tetano
Editor, Senior Moderator
J Pediatric Infect Dis Soc. 2020 Apr 22. pii: piaa045. doi: 10.1093/jpids/piaa045. [Epub ahead of print]
Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2.
Chiotos K[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Hayes M[SUP]3[/SUP], Kimberlin DW[SUP]4[/SUP], Jones SB[SUP]5,[/SUP][SUP]6[/SUP], James SH[SUP]4[/SUP], Pinninti SG[SUP]4[/SUP], Yarbrough A[SUP]7[/SUP], Abzug MJ[SUP]8[/SUP], MacBrayne CE[SUP]9[/SUP], Soma VL[SUP]10[/SUP], Dulek DE[SUP]11[/SUP], Vora SB[SUP]12[/SUP], Waghmare A[SUP]12,[/SUP][SUP]13[/SUP], Wolf J[SUP]14[/SUP], Olivero R[SUP]15[/SUP], Grapentine S[SUP]16[/SUP], Wattier RL[SUP]17[/SUP], Bio L[SUP]18[/SUP], Cross SJ[SUP]19[/SUP], Dillman NO[SUP]20[/SUP], Downes KJ[SUP]2[/SUP], Timberlake K[SUP]21[/SUP], Young J[SUP]22[/SUP], Orscheln RC[SUP]23[/SUP], Tamma PD[SUP]24[/SUP], Schwenk HT[SUP]25[/SUP], Zachariah P[SUP]26[/SUP], Aldrich M[SUP]27[/SUP], Goldman DL[SUP]27[/SUP], Groves HE[SUP]28[/SUP], Lamb GS[SUP]29[/SUP], Tribble AC[SUP]30[/SUP], Hersh AL[SUP]31[/SUP], Thorell EA[SUP]31[/SUP], Denison MR[SUP]11[/SUP], Ratner AJ[SUP]10,[/SUP][SUP]32[/SUP], Newland JG[SUP]23[/SUP], Nakamura MM[SUP]6,[/SUP][SUP]29[/SUP].
Author information
Abstract
BACKGROUND:
Although Coronavirus Disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develops severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics.
METHODS:
A panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of best available evidence and expert opinion.
RESULTS:
Given the typically mild course of pediatric COVID-19, supportive care alone is suggested for the overwhelming majority of cases. The panel suggests a decision-making framework for antiviral therapy that weighs risks and benefits based on disease severity as indicated by respiratory support needs, with consideration on a case-by-case basis of potential pediatric risk factors for disease progression. If an antiviral is used, the panel suggests remdesivir as the preferred agent. Hydroxychloroquine could be considered for patients who are not candidates for remdesivir or when remdesivir is not available. Antivirals should preferably be used as part of a clinical trial if available.
CONCLUSIONS:
Antiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. For those rare children who develop severe or critical disease, this guidance offer an approach for decision-making regarding antivirals, informed by available data. As evidence continues to evolve rapidly, the need for updates to the guidance is anticipated.
? The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
KEYWORDS:
COVID-19; SARS-CoV-2; antiviral; guidance; pediatric
PMID:32318706DOI:10.1093/jpids/piaa045
Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2.
Chiotos K[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Hayes M[SUP]3[/SUP], Kimberlin DW[SUP]4[/SUP], Jones SB[SUP]5,[/SUP][SUP]6[/SUP], James SH[SUP]4[/SUP], Pinninti SG[SUP]4[/SUP], Yarbrough A[SUP]7[/SUP], Abzug MJ[SUP]8[/SUP], MacBrayne CE[SUP]9[/SUP], Soma VL[SUP]10[/SUP], Dulek DE[SUP]11[/SUP], Vora SB[SUP]12[/SUP], Waghmare A[SUP]12,[/SUP][SUP]13[/SUP], Wolf J[SUP]14[/SUP], Olivero R[SUP]15[/SUP], Grapentine S[SUP]16[/SUP], Wattier RL[SUP]17[/SUP], Bio L[SUP]18[/SUP], Cross SJ[SUP]19[/SUP], Dillman NO[SUP]20[/SUP], Downes KJ[SUP]2[/SUP], Timberlake K[SUP]21[/SUP], Young J[SUP]22[/SUP], Orscheln RC[SUP]23[/SUP], Tamma PD[SUP]24[/SUP], Schwenk HT[SUP]25[/SUP], Zachariah P[SUP]26[/SUP], Aldrich M[SUP]27[/SUP], Goldman DL[SUP]27[/SUP], Groves HE[SUP]28[/SUP], Lamb GS[SUP]29[/SUP], Tribble AC[SUP]30[/SUP], Hersh AL[SUP]31[/SUP], Thorell EA[SUP]31[/SUP], Denison MR[SUP]11[/SUP], Ratner AJ[SUP]10,[/SUP][SUP]32[/SUP], Newland JG[SUP]23[/SUP], Nakamura MM[SUP]6,[/SUP][SUP]29[/SUP].
Author information
Abstract
BACKGROUND:
Although Coronavirus Disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develops severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics.
METHODS:
A panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of best available evidence and expert opinion.
RESULTS:
Given the typically mild course of pediatric COVID-19, supportive care alone is suggested for the overwhelming majority of cases. The panel suggests a decision-making framework for antiviral therapy that weighs risks and benefits based on disease severity as indicated by respiratory support needs, with consideration on a case-by-case basis of potential pediatric risk factors for disease progression. If an antiviral is used, the panel suggests remdesivir as the preferred agent. Hydroxychloroquine could be considered for patients who are not candidates for remdesivir or when remdesivir is not available. Antivirals should preferably be used as part of a clinical trial if available.
CONCLUSIONS:
Antiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. For those rare children who develop severe or critical disease, this guidance offer an approach for decision-making regarding antivirals, informed by available data. As evidence continues to evolve rapidly, the need for updates to the guidance is anticipated.
? The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
KEYWORDS:
COVID-19; SARS-CoV-2; antiviral; guidance; pediatric
PMID:32318706DOI:10.1093/jpids/piaa045